MedTrace Logo

Efficacy of Losartan in Preventing Progression of COPD

NCT00720226 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 106

Last updated 2017-04-25

Study results available
· View outcomes & findings →

Summary

Evidence in animals shows that losartan can prevent or reverse inflammation and lung damage due to smoking. The goal of this study is to determine whether this drug which is also used to treat hypertension can stabilize or improve lung function in people who have from chronic obstructive pulmonary disease (COPD).

Conditions

  • COPD
  • Emphysema
  • Chronic Bronchitis
  • Smoking

Interventions

DRUG

Losartan

Losartan 100 mg daily

DRUG

Placebo

Placebo pill daily

Sponsors & Collaborators

Principal Investigators

  • Robert A. Wise, MD · Johns Hopkins University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
40 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-07-31
Primary Completion
2014-08-31
Completion
2016-08-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00720226 on ClinicalTrials.gov